Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07181135
PHASE3

FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors

Sponsor: University Medical Center Groningen

View on ClinicalTrials.gov

Summary

Study to demonstrate efficacy of finerenone when compared to placebo in reducing albuminuria in participants with chronic kidney disease (CKD) not using renin-angiotensin-system (RAS) inhibitors.

Official title: A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Participants With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

180

Start Date

2026-03-23

Completion Date

2027-12-31

Last Updated

2026-04-01

Healthy Volunteers

No

Interventions

DRUG

Finerenone (BAY 94-8862)

Finerenone 10 or 20mg in participants with chronic kidney disease not using renin-angiotensin-system inhibitors

DRUG

Placebo

Placebo matching finerenone

Locations (8)

Hospital Universitari Germans Trias i Pujol

Barcelona, Spain

Vall d'Hebron University Hospital

Barcelona, Spain

Clínica Universidad de Navarra

Madrid, Spain

Hospital Universitario de La Princesa

Madrid, Spain

Hospital Universitario Puerta de Hierro

Madrid, Spain

Clínica Universidad de Navarra

Pamplona, Spain

Hospital Clinico Universitario de Valencia

Valencia, Spain

Hospital Universitario Dr Peset

Valencia, Spain